A Study of Niraparib in Patients With Relapsed Ovarian Cancer
NCT04392102
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
ZL-2306(Niraparib)
Sponsor
Zai Lab (Shanghai) Co., Ltd.